Investment, Funding & Disinvestments

SPARK-NCD addresses undiagnosed high blood pressure or diabetes by improving monitoring systems, training a skilled public health team, and integrating chronic disease information into current national health systems.

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

Jeito II will back between 15 and 20 clinical-stage biopharma companies, primarily in Europe, with average investments of up to €150 million (USD180 million) per company

Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.

EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.

Implementing these programs under Africa CDC leadership will enhance disease surveillance systems, expand laboratory infrastructure, and foster deeper partnerships with leading European research institutions.

The hospital’s construction was originally scheduled to begin in 2024, with the first phase of the 500-bed facility targeted for completion in December 2025.

The contract includes multiyear options that could ultimately deliver up to USD 482 million if exercised, enabling Shionogi to establish a dedicated manufacturing facility in the United States.

BioNTech’s decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction

The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.